Edward Kerwin

机构：Clinical Research Institute, Dermatology Research Center · ORCID：0000-0002-1697-9036

发表论文 282 篇 · 总被引 7812 次 · h-index 37

代表论文

• Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial (2021 · The Lancet Respiratory Medicine · 被引 628)
• Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial (2020 · The Lancet Respiratory Medicine · 被引 268)
• Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study (2023 · The Lancet Respiratory Medicine · 被引 158)
• Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F (RSVPreF3) Candidate Vaccine in Older Adults: Phase 1/2 Randomized Clinical Trial (2022 · The Journal of Infectious Diseases · 被引 124)
• Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): a randomised, placebo-controlled, phase 2a trial (2024 · The Lancet Respiratory Medicine · 被引 82)
• CXCR2 antagonist for patients with chronic obstructive pulmonary disease with chronic mucus hypersecretion: a phase 2b trial (2020 · Respiratory Research · 被引 73)